卡培他滨和替吉奥在晚期胃癌一线诱导化疗后维持治疗的疗效及安全性对比

目的 研究晚期胃癌患者一线诱导化疗后应用卡培他滨或替吉奥维持治疗的疗效及安全性.方法 155例晚期胃癌患者,均接受一线诱导化疗后病情得到控制,根据维持治疗的药物不同分为卡培他滨组(76例)与替吉奥组(79例).卡培他滨组采用卡培他滨治疗,替吉奥组采用替吉奥治疗.比较两组的近期疾病控制率、不良反应发生率、远期疗效指标.结...

Comparison of efficacy and safety of capecitabine and tegafur,gimeracil and oteracil porassium in maintenance therapy after first-line induction chemotherapy for advanced gastric cancer

Objective To study the efficacy and safety of capecitabine and tegafur,gimeracil and oteracil porassium(TS1)in maintenance therapy after first-line induction chemotherapy for advanced gastric cancer.Methods 155 patients with advanced gastric cancer received first-line induction chemotherapy and their condition was controlled.According to different drugs for maintenance treatment,they were divided into capecitabine group(76 cases)and TS1 group(79 cases).The capecitabine group was treated with capecitabine,and the TS1 group was treated with capecitabine and tegafur,gimeracil and oteracil porassium.The short-term disease control rate,occurrence of adverse reactions,and long-term efficacy indicators of the two groups were compared.Results The difference in short-term disease control rate 80.26% in the capecitabine group was not statistically significant compared with 79.75% in the TS1 group(P>0.05).There was no statistically significant difference in the incidence of leukopenia,anemia,thrombocytopenia,gastrointestinal discomfort,hand-foot syndrome,liver damage,and fatigue between the two groups(P>0.05).The adverse reactions of the two groups were mainly grade 1-2,and a few patients had grade 3-4 adverse reactions,and there was no treatment-related death.The overall survival time of the capecitabine group was(16.1±2.3)months,and the disease progression time was(8.6±1.4)months;the overall survival time of the TS1 group was(16.5±2.4)months,and the disease progression time was(9.0±1.6)months;the differences in overall survival time and disease progression time between the two groups were not statistically significant(P>0.05).Conclusion Capecitabine and TS1 are effective in maintenance therapy after first-line induction chemotherapy in patients with advanced gastric cancer,which is contribute to prolonging the survival of patients,and there are a few adverse reactions.